EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

Journal of Hepatology

Volumn 67, Issue 1, 2017, Pages 145-172

  Hirschfield, Gideon M ^a   Beuers, Ulrich ^a   Corpechot, Christophe ^a   Invernizzi, Pietro ^a   Jones, David ^a   Marzioni, Marco ^a   Schramm, Christoph ^a  

^a NONE

Author keywords

Care pathway; Cholestasis; Guidelines; Liver

Indexed keywords

BILIRUBIN; BIOLOGICAL MARKER; BUDESONIDE; FIBRIC ACID DERIVATIVE; OBETICHOLIC ACID; URSODEOXYCHOLIC ACID;

ABDOMINAL RADIOGRAPHY; ANAMNESIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; BIOCHEMICAL ANALYSIS; CHOLANGIOCELLULAR CHOLESTASIS; CHOLANGITIS; COCHRANE LIBRARY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; END STAGE LIVER DISEASE; FATIGUE; GENETIC SCREENING; HEALTH CARE DELIVERY; HEPATOCELLULAR CHOLESTASIS; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; INFORMATION RETRIEVAL; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LIVER STIFFNESS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MEDLINE; OFF LABEL DRUG USE; OSTEOPOROSIS; PATIENT CARE; PHARMACEUTICAL CARE; PHYSICAL EXAMINATION; PORTAL VEIN BLOOD PRESSURE; PRACTICE GUIDELINE; PREGNANCY; PRIMARY BILIARY CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RISK ASSESSMENT; SCORING SYSTEM; SEROLOGY; SICCA COMPLEX; SYMPTOM; VARICOSIS; VITAMIN SUPPLEMENTATION; COMPLICATION; FEMALE; MALE;

CHOLANGITIS; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; URSODEOXYCHOLIC ACID;

EID: 85017552637     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.03.022     Document Type: Article

References (261)

1. Beuers, U., Gershwin, M.E., Gish, R.G., Invernizzi, P., Jones, D.E., Lindor, K., et al. Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’. J Hepatol 63 (2015), 1285–1287.
2. Selmi, C., Bowlus, C.L., Gershwin, M.E., Coppel, R.L., Primary biliary cirrhosis. Lancet 377 (2011), 1600–1609.
3. Hirschfield, G.M., Gershwin, M.E., The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 8 (2013), 303–330.
4. Beuers, U., Trauner, M., Jansen, P., Poupon, R., New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 62 (2015), S25–S37.
5. Webb, G.J., Hirschfield, G.M., Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances. Nat Rev Gastroenterol Hepatol 14 (2017), 76–78.
6. Carbone, M., Mells, G.F., Pells, G., Dawwas, M.F., Newton, J.L., Heneghan, M.A., et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic Acid. Gastroenterology 144 (2013), 560–569.
7. Lammers, W.J., van Buuren, H.R., Hirschfield, G.M., Janssen, H.L., Invernizzi, P., Mason, A.L., et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 147 (2014), 1338–1349.
8. Trivedi, P.J., Lammers, W.J., van Buuren, H.R., Pares, A., Floreani, A., Janssen, H.L., et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 65 (2016), 321–329.
9. Dahlan, Y., Smith, L., Simmonds, D., Jewell, L.D., Wanless, I., Heathcote, E.J., et al. Pediatric-onset primary biliary cirrhosis. Gastroenterology 125 (2003), 1476–1479.
10. Invernizzi, P., Alessio, M.G., Smyk, D.S., Lleo, A., Sonzogni, A., Fabris, L., et al. Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. BMC Gastroenterol, 12, 2012, 92.
11. Juran, B.D., Lazaridis, K.N., Environmental factors in primary biliary cirrhosis. Semin Liver Dis 34 (2014), 265–272.
12. Webb, G.J., Hirschfield, G.M., Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimmun 66 (2016), 25–39.
13. Bianchi, I., Carbone, M., Lleo, A., Invernizzi, P., Genetics and epigenetics of primary biliary cirrhosis. Semin Liver Dis 34 (2014), 255–264.
14. Jepsen, P., Gronbaek, L., Vilstrup, H., Worldwide incidence of autoimmune liver disease. Dig Dis 33 (2015), 2–12.
15. Boonstra, K., Kunst, A.E., Stadhouders, P.H., Tuynman, H.A., Poen, A.C., van Nieuwkerk, K.M., et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int 34 (2014), e31–e38.
16. Griffiths, L., Dyson, J.K., Jones, D.E., The new epidemiology of primary biliary cirrhosis. Semin Liver Dis 34 (2014), 318–328.
17. Dahlqvist, G., Gaouar, F., Carrat, F., Meurisse, S., Chazouilleres, O., Poupon, R., et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology 65 (2017), 152–163.
18. Lleo, A., Jepsen, P., Morenghi, E., Carbone, M., Moroni, L., Battezzati, P.M., et al. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep, 6, 2016, 25906.
19. Bianchi, I., Lleo, A., Gershwin, M.E., Invernizzi, P., The X chromosome and immune associated genes. J Autoimmun 38 (2012), J187–J192.
20. Trivedi, P.J., Corpechot, C., Pares, A., Hirschfield, G.M., Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. Hepatology 63 (2016), 644–659.
21. Trauner, M., Fuchs, C.D., Halilbasic, E., Paumgartner, G., New therapeutic concepts in bile acid transport and signalling for management of cholestasis. Hepatology 65 (2017), 1393–1404.
22. Jansen, P.L., Ghallab, A., Vartak, N., Reif, R., Schaap, F.G., Hampe, J., et al. The ascending pathophysiology of cholestatic liver disease. Hepatology 65 (2017), 722–738.
23. Hirschfield, G.M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., et al. Primary biliary cirrhosis associated with HLA, IL12A and IL12RB2 variants. N Engl J Med 360 (2009), 2544–2555.
24. Cordell, H.J., Han, Y., Mells, G.F., Li, Y., Hirschfield, G.M., Greene, C.S., et al. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nat Commun, 6, 2015, 8019.
25. Chang, J.C., Go, S., de Waart, D.R., Munoz-Garrido, P., Beuers, U., Paulusma, C.C., et al. Soluble adenylyl cyclase regulates bile salt-induced apoptosis in human cholangiocytes. Hepatology 64 (2016), 522–534.
26. Hisamoto, S., Shimoda, S., Harada, K., Iwasaka, S., Onohara, S., Chong, Y., et al. Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis. J Autoimmun 75 (2016), 150–160.
27. Beuers, U., Hohenester, S., de Buy Wenniger, L.J., Kremer, A.E., Jansen, P.L., Elferink, R.P., The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 52 (2010), 1489–1496.
28. Poupon, R., Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation. Hepatology 61 (2015), 2080–2090.
29. Mells, G., Pells, G., Newton, J.L., Heneghan, M., Neuberger, J.M., Day, D., et al. The impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC National Study. Hepatology 58 (2013), 273–283.
30. Dyson, J.K., Wilkinson, N., Jopson, L., Mells, G., Bathgate, A., Heneghan, M.A., et al. The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. Aliment Pharmacol Ther 44 (2016), 1039–1050.
31. Prince, M.I., Chetwynd, A., Newman, W., Metcalf, J.V., James, O.F., Survival and symptom progression in a geographically based cohort of paients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 123 (2002), 1044–1051.
32. Mahl, T.C., Shockcor, W., Boyer, J.L., Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 20 (1994), 707–713.
33. Christensen, E., Crowe, J., Doniach, D., Popper, H., Ranek, L., Rodes, J., et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 78 (1980), 236–246.
34. Locke, G.R. 3rd, Therneau, T.M., Ludwig, J., Dickson, E.R., Lindor, K.D., Time course of histological progression in primary biliary cirrhosis. Hepatology 23 (1996), 52–56.
35. Corpechot, C., Carrat, F., Bonnand, A.M., Poupon, R.E., Poupon, R., The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32 (2000), 1196–1199.
36. Shaneyfelt, T.M., Mayo-Smith, M.F., Rothwangl, J., Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 281 (1999), 1900–1905.
37. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51 (2009), 237–267.
38. Chalasani, N.P., Hayashi, P.H., Bonkovsky, H.L., Navarro, V.J., Lee, W.M., Fontana, R.J., et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 109 (2014), 950–966.
39. Oertelt, S., Rieger, R., Selmi, C., Invernizzi, P., Ansari, A.A., Coppel, R.L., et al. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology 45 (2007), 659–665.
40. Liu, H., Norman, G.L., Shums, Z., Worman, H.J., Krawitt, E.L., Bizzaro, N., et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun 35 (2010), 436–442.
41. Leung, P.S., Rossaro, L., Davis, P.A., Park, O., Tanaka, A., Kikuchi, K., et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology 46 (2007), 1436–1442.
42. Mattalia, A., Quaranta, S., Leung, P.S., Bauducci, M., Van de Water, J., Calvo, P.L., et al. Characterization of antimitochondrial antibodies in health adults. Hepatology 27 (1998), 656–661.
43. Ohba, K., Omagari, K., Kinoshita, H., Soda, H., Masuda, J., Hazama, H., et al. Primary biliary cirrhosis among atomic bomb survivors in Nagasaki, Japan. J Clin Epidemiol 54 (2001), 845–850.
44. Ong, J., Erdei, E., Rubin, R.L., Miller, C., Ducheneaux, C., O'Leary, M., et al. Mercury, autoimmunity, and environmental factors on cheyenne river sioux tribal lands. Autoimmune Dis, 2014, 2014, 325461.
45. Lleo, A., Liao, J., Invernizzi, P., Zhao, M., Bernuzzi, F., Ma, L., et al. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology 55 (2012), 153–160.
46. Christensen, E., Neuberger, J., Crowe, J., Portmann, B., Williams, R., Altman, D.G., et al. Azathioprine and prognosis in primary biliary cirrhosis. Gastroenterology 90 (1986), 508–509.
47. Poupon, R., Chazouilleres, O., Balkau, B., Poupon, R.E., Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis, UDCA-PBC Group. J Hepatol 30 (1999), 408–412.
48. Corpechot, C., Poujol-Robert, A., Wendum, D., Galotte, M., Chretien, Y., Poupon, R.E., et al. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int 24 (2004), 187–193.
49. Longo, M., Crosignani, A., Battezzati, P.M., Squarcia Giussani, C., Invernizzi, P., Zuin, M., et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 51 (2002), 265–269.
50. Allocca, M., Crosignani, A., Gritti, A., Ghilardi, G., Gobatti, D., Caruso, D., et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 55 (2006), 1795–1800.
51. Vergani, D., Alvarez, F., Bianchi, F.B., Cancado, E.L., Mackay, I.R., Manns, M.P., et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 41 (2004), 677–683.
52. Invernizzi, P., Lleo, A., Podda, M., Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis 27 (2007), 161–172.
53. Metcalf, J.V., Mitchinson, H.C., Palmer, J.M., Jones, D.E.J., Bassendine, M.F., James, O.F.W., Natural history of early primary biliary cirrhosis. Lancet 348 (1996), 1399–1402.
54. Hirschfield, G.M., Heathcote, E.J., Antimitochondrial antibody-negative primary biliary cirrhosis. Clin Liver Dis 12 (2008), 323–331.
55. Ludwig, J., Dickson, E.R., McDonald, G.S., Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch 379 (1978), 103–112.
56. Scheuer, P., Primary biliary cirrhosis. Proc R Soc Med 60 (1967), 1257–1260.
57. Scheuer, P.J., Ludwig Symposium on biliary disorders–part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. Mayo Clin Proc 73 (1998), 179–183.
58. Nakanuma, Y., Zen, Y., Harada, K., Sasaki, M., Nonomura, A., Uehara, T., et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int 60 (2010), 167–174.
59. Harada, K., Hsu, M., Ikeda, H., Zeniya, M., Nakanuma, Y., Application and validation of a new histologic staging and grading system for primary biliary cirrhosis. J Clin Gastroenterol 47 (2013), 174–181.
60. Kakuda, Y., Harada, K., Sawada-Kitamura, S., Ikeda, H., Sato, Y., Sasaki, M., et al. Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Hum Pathol 44 (2013), 1107–1117.
61. ter Borg, P.C., Schalm, S.W., Hansen, B.E., van Buuren, H.R., Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 101 (2006), 2044–2050.
62. Pares, A., Caballeria, L., Rodes, J., Excellent long-term survival in patients with primary biliary cirrhosisand biochemical response to ursodeoxycholic acid. Gastroenterology 130 (2006), 715–720.
63. Corpechot, C., Abenavoli, L., Rabahi, N., Chretien, Y., Andreani, T., Johanet, C., et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48 (2008), 871–877.
64. Kubota, J., Ikeda, F., Terada, R., Kobashi, H., Fujioka, S., Okamoto, R., et al. Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population. J Gastroenterol 44 (2009), 1000–1006.
65. Cheung, A., Lammers, W.J., Hirschfield, G.M., Invernizzi, P., Mason, A., Ponsioen, C.Y., et al. Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis. J Hepatol 62 (2015), S798–S799.
66. Quarneti, C., Muratori, P., Lalanne, C., Fabbri, A., Menichella, R., Granito, A., et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int 35 (2015), 636–641.
67. Jones, D.E., Al-Rifai, A., Frith, J., Patanwala, I., Newton, J.L., The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: Results of a 9 year follow-up. J Hepatol 53 (2010), 911–917.
68. Vleggaar, F.P., van Buuren, H.R., Zondervan, P.E., ten Kate, F.J., Hop, W.C., Dutch Multicentre PBC study group. Jaundice in non-cirrhotic primary bilairy cirrhosis: the premature ductopenic variant. Gut 49 (2001), 276–281.
69. Jones, D.E., Bhala, N., Burt, J., Goldblatt, J., Prince, M., Newton, J.L., Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 55 (2006), 536–541.
70. Prince, M.I., Chetwynd, A., Craig, W.L., Metcalf, J.V., James, O.F., Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 53 (2004), 865–870.
71. Newton, J., Jones, D.E., Variability of perceived fatigue in primary biliary cirrhosis: implications for symptom assessment. Liver Int 30 (2010), 333–334.
72. Shapiro, J.M., Smith, H., Schaffner, F., Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 20 (1979), 137–140.
73. Kilmurry, M.R., Heathcote, E.J., Cauch-Dudek, K., O'Rourke, K., Bailey, R.J., Blendis, L.M., et al. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?. Hepatology 23 (1996), 1148–1153.
74. Mayo, M.J., Parkes, J., Adams-Huet, B., Combes, B., Mills, A.S., Markin, R.S., et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 48 (2008), 1549–1557.
75. Muratori, P., Muratori, L., Ferrari, R., Cassani, F., Bianchi, G., Lenzi, M., et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 98 (2003), 431–437.
76. Rigopoulou, E.I., Davies, E.T., Pares, A., Zachou, K., Liaskos, C., Bogdanos, D.P., et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 54 (2005), 528–532.
77. Wesierska-Gadek, J., Penner, E., Battezzati, P.M., Selmi, C., Zuin, M., Hitchman, E., et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 43 (2006), 1135–1144.
78. Nakamura, M., Kondo, H., Tanaka, A., Komori, A., Ito, M., Yamamoto, K., et al. Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis. Hepatol Res 45 (2015), 846–855.
79. Rigamonti, C., Shand, L.M., Feudjo, M., Bunn, C.C., Black, C.M., Denton, C.P., et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 55 (2006), 388–394.
80. Nakamura, M., Kondo, H., Mori, T., Komori, A., Matsuyama, M., Ito, M., et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45 (2007), 118–127.
81. Nyberg, A., Engstrom-Laurent, A., Loof, L., Serum hyaluronate in primary biliary cirrhosis–a biochemical marker for progressive liver damage. Hepatology 8 (1988), 142–146.
82. Poupon, R.E., Balkau, B., Guechot, J., Heintzmann, F., Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue. Hepatology 19 (1994), 635–640.
83. Trivedi, P.J., Bruns, T., Cheung, A., Li, K.K., Kittler, C., Kumagi, T., et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J Hepatol 60 (2014), 1249–1258.
84. Umemura, T., Joshita, S., Sekiguchi, T., Usami, Y., Shibata, S., Kimura, T., et al. Serum wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol 110 (2015), 857–864.
85. Sekiguchi, T., Umemura, T., Fujimori, N., Shibata, S., Ichikawa, Y., Kimura, T., et al. Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis. PLoS One, 10, 2015, e0131658.
86. Corpechot, C., Carrat, F., Poujol-Robert, A., Gaouar, F., Wendum, D., Chazouilleres, O., et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 56 (2012), 198–208.
87. Floreani, A., Cazzagon, N., Martines, D., Cavalletto, L., Baldo, V., Chemello, L., Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. Dig Liver Dis 43 (2011), 887–892.
88. Gomez-Dominguez, E., Mendoza, J., Garcia-Buey, L., Trapero, M., Gisbert, J.P., Jones, E.A., et al. Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Aliment Pharmacol Ther 27 (2008), 441–447.
89. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63 (2015), 237–264.
90. Corpechot, C., Gaouar, F., Lemoinne, S., Ben Belkacem, K., Kemgang Fankem, A., Chretien, Y., et al. Relationships between biochemical response to UDCA and progression of liver stiffness as determined by Fibroscan in patients with PBC. Hepatology 64 (2016), 194A–195A.
91. Corpechot, C., Gaouar, F., Lemoinne, S., Kemgang Fankem, A., Poupon, R., Chretien, Y., et al. Fibroscan improves the ability of the new prognostic scoring systems to predict outcomes of PBC. J Hepatol 64 (2016), S177–S178.
92. Boursier, J., Zarski, J.P., de Ledinghen, V., Rousselet, M.C., Sturm, N., Lebail, B., et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 57 (2013), 1182–1191.
93. Roll, J., Boyer, J.L., Barry, D., Klatskin, G., The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 308 (1983), 1–7.
94. Poupon, R.E., Bonnand, A.M., Chretien, Y., Poupon, R., Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Hepatology 29 (1999), 1668–1671.
95. Carbone, M., Sharpe, S.J., Heneghan, M.A., Neuberger, J., Hirschfield, G.M., Burroughs, A., et al. Histological stage is relevant for risk-stratification in primary biliary cirrhosis. J Hepatol, 62, 2015, S805.
96. Rabahi, N., Chretien, Y., Gaouar, F., Wendum, D., Serfaty, L., Chazouilleres, O., et al. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol 34 (2010), 283–287.
97. Corpechot, C., Carrat, F., Poupon, R., Poupon, R.E., Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 122 (2002), 652–658.
98. Kumagi, T., Guindi, M., Fischer, S.E., Arenovich, T., Abdalian, R., Coltescu, C., et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 105 (2010), 2186–2194.
99. Huet, P.M., Vincent, C., Deslaurier, J., Cote, J., Matsutami, S., Boileau, R., et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology 135 (2008), 1552–1560.
100. Silveira, M.G., Brunt, E.M., Heathcote, J., Gores, G.J., Lindor, K.D., Mayo, M.J., American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 52 (2010), 349–359.
101. Angulo, P., Lindor, K.D., Therneau, T.M., Jorgensen, R.A., Malinchoc, M., Kamath, P.S., et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 19 (1999), 115–121.
102. Kuiper, E.M., Hansen, B.E., de Vries, R.A., den Ouden-Muller, J.W., van Ditzhuijsen, T.J., Haagsma, E.B., et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 136 (2009), 1281–1287.
103. Azemoto, N., Abe, M., Murata, Y., Hiasa, Y., Hamada, M., Matsuura, B., et al. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol 44 (2009), 630–634.
104. Corpechot, C., Chazouilleres, O., Poupon, R., Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 55 (2011), 1361–1367.
105. Zhang, L.N., Shi, T.Y., Shi, X.H., Wang, L., Yang, Y.J., Liu, B., et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology 58 (2013), 264–272.
106. Lammers, W.J., Hirschfield, G.M., Corpechot, C., Nevens, F., Lindor, K.D., Janssen, H.L., et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 149 (2015), 1804–1812.
107. Carbone, M., Sharp, S.J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., et al. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis. Hepatology 63 (2016), 930–950.
108. Hansen, B., Lammers, W.J., Jones, D., van Buuren, H., Mells, G.F., Carbone, M., Convergence of Two Predictive Models of Risk Reduction in Patients with Primary Biliary Cirrhosis. Hepatology, 62, 2016, 507A.
109. Lindor, K., Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 357 (2007), 1524–1529.
110. Lindor, K.D., Gershwin, M.E., Poupon, R., Kaplan, M., Bergasa, N., Heathcote, E., Primary biliary cirrhosis. Hepatology 50 (2009), 291–308.
111. Hirschfield, G.M., Heathcote, E.J., (eds.) Primary biliary cirrhosis: evidence-based gastroenterology and hepatology, 3rd ed., 2010, Wiley-Blackwell, Oxford, UK, 10.1002/9781444314403 Chapter 3.
112. Poupon, R.E., Poupon, R., Balkau, B., Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 330 (1994), 1342–1347.
113. Lindor, K.D., Dickson, E.R., Baldus, W.P., Jorgensen, R.A., Ludwig, J., Murtaugh, P.A., et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106 (1994), 1284–1290.
114. Heathcote, E.J., Cauch-Dudek, K., Walker, V., Bailey, R.J., Blendis, L.M., Ghent, C.N., et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19 (1994), 1149–1156.
115. Turner, I.B., Myszor, M., Mitchison, H.C., Bennett, M.K., Burt, A.D., James, O.F., A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol 9 (1994), 162–168.
116. Poupon, R.E., Lindor, K.D., Cauch-Dudek, K., Dickson, E.R., Poupon, R., Heathcote, E.J., Combined analysis of randomized trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113 (1997), 884–890.
117. Combes, B., Carithers, R.L. Jr., Maddrey, W.C., Lin, D., McDonald, M.F., Wheeler, D.E., et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22 (1995), 759–766.
118. Van Hoogstraten, H.J., De Smet, M.B., Renooij, W., Breed, J.G., Engels, L.G., Den Ouden-Muller, J.W., et al. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group. Aliment Pharmacol Ther 12 (1998), 965–971.
119. Goulis, J., Leandro, G., Burroughs, A.K., Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354 (1999), 1053–1060.
120. Shi, J., Wu, C., Lin, Y., Chen, Y.X., Zhu, L., Xie, W.F., Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 101 (2006), 1529–1538.
121. Rudic, J.S., Poropat, G., Krstic, M.N., Bjelakovic, G., Gluud, C., Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev, 12, 2012, CD000551.
122. Beuers, U., Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 3 (2006), 318–328.
123. Gohlke, H., Schmitz, B., Sommerfeld, A., Reinehr, R., Haussinger, D., alpha5 beta1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes. Hepatology 57 (2013), 1117–1129.
124. Dilger, K., Hohenester, S., Winkler-Budenhofer, U., Bastiaansen, B.A., Schaap, F.G., Rust, C., et al. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol 57 (2012), 133–140.
125. Kondrackiene, J., Beuers, U., Kupcinskas, L., Efficacy and safety of ursodeoxycholic acid vs. cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129 (2005), 894–901.
126. Bacq, Y., Sentilhes, L., Reyes, H.B., Glantz, A., Kondrackiene, J., Binder, T., et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology 143 (2012), 1492–1501.
127. Gong, Y., Huang, Z., Christensen, E., Gluud, C., Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 102 (2007), 1799–1807.
128. Schaap, F.G., Trauner, M., Jansen, P.L., Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 11 (2014), 55–67.
129. Gomez-Ospina, N., Potter, C.J., Xiao, R., Manickam, K., Kim, M.S., Kim, K.H., et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun, 7, 2016, 10713.
130. Hirschfield, G.M., Mason, A., Luketic, V., Lindor, K., Gordon, S.C., Mayo, M., et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148 (2015), 751–761.
131. Nevens, F., Andreone, P., Mazzella, G., Strasser, S.I., Bowlus, C., Invernizzi, P., et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 375 (2016), 631–643.
132. Hempfling, W., Grunhage, F., Dilger, K., Reichel, C., Beuers, U., Sauerbruch, T., Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 38 (2003), 196–202.
133. Arenas, F., Hervias, I., Uriz, M., Joplin, R., Prieto, J., Medina, J.F., Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest 118 (2008), 695–709.
134. Leuschner, M., Maier, K.P., Schlichting, J., Strahl, S., Herrmann, G., Dahm, H.H., et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 117 (1999), 918–925.
135. Rautiainen, H., Karkkainen, P., Karvonen, A.L., Nurmi, H., Pikkarainen, P., Nuutinen, H., et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 41 (2005), 747–752.
136. Angulo, P., Jorgensen, R.A., Keach, J.C., Dickson, E.R., Smith, C., Lindor, K.D., Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 31 (2000), 318–323.
137. Zhu, G.Q., Huang, S., Huang, G.Q., Wang, L.R., Lin, Y.Q., Wu, Y.M., et al. Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis. Oncotarget 6 (2015), 24533–24549.
138. Zhu, G.Q., Shi, K.Q., Huang, S., Huang, G.Q., Lin, Y.Q., Zhou, Z.R., et al. Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis. Medicine, 94, 2015, e609.
139. Ghonem, N.S., Assis, D.N., Boyer, J.L., Fibrates and cholestasis. Hepatology 62 (2015), 635–643.
140. Yin, Q., Li, J., Xia, Y., Zhang, R., Wang, J., Lu, W., et al. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis. Drug Des Devel Ther 9 (2015), 5407–5419.
141. Tanaka, A., Hirohara, J., Nakanuma, Y., Tsubouchi, H., Takikawa, H., Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. J Gastroenterol 50 (2015), 675–682.
142. Kanda, T., Yokosuka, O., Imazeki, F., Saisho, H., Bezafibrate treatment: a new medical approach for PBC patients?. J Gastroenterol 38 (2003), 573–578.
143. Hosonuma, K., Sato, K., Yamazaki, Y., Yanagisawa, M., Hashizume, H., Horiguchi, N., et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol 110 (2015), 423–431.
144. Lens, S., Leoz, M., Nazal, L., Bruguera, M., Pares, A., Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int 34 (2014), 197–203.
145. Ohira, H., Sato, Y., Ueno, T., Sata, M., Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol 97 (2002), 2147–2149.
146. Levy, C., Peter, J.A., Nelson, D.R., Keach, J., Petz, J., Cabrera, R., et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 33 (2011), 235–242.
147. Grigorian, A.Y., Mardini, H.E., Corpechot, C., Poupon, R., Levy, C., Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis. Clin Res Hepatol Gastroenterol 39 (2015), 296–306.
148. Cheung, A.C., Lapointe-Shaw, L., Kowgier, M., Meza-Cardona, J., Hirschfield, G.M., Janssen, H.L., et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther 43 (2016), 283–293.
149. Yano, K., Kato, H., Morita, S., Takahara, O., Ishibashi, H., Furukawa, R., Is bezafibrate histologically effective for primary biliary cirrhosis?. Am J Gastroenterol 97 (2002), 1075–1077.
150. Kurihara, T., Maeda, A., Shigemoto, M., Yamashita, K., Hashimoto, E., Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol 97 (2002), 212–214.
151. Hegade, V.S., Khanna, A., Walker, L.J., Wong, L.L., Dyson, J.K., Jones, D.E., Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but Not the UK-PBC risk score. Dig Dis Sci 61 (2016), 3037–3044.
152. Zhang, Y., Li, S., He, L., Wang, F., Chen, K., Li, J., et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis. Drug Des Devel Ther 9 (2015), 2757–2766.
153. Trivedi, P.J., Kumagi, T., Al-Harthy, N., Coltescu, C., Ward, S., Cheung, A., et al. Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis. Clin Gastroenterol Hepatol 12 (2014), 1179–1185.
154. Geenes, V., Chambers, J., Khurana, R., Shemer, E.W., Sia, W., Mandair, D., et al. Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy. Eur J Obstet Gynecol Reprod Biol 189 (2015), 59–63.
155. Alallam, A., Barth, D., Heathcote, E.J., Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can J Gastroenterol, 2008, 505–507.
156. Boberg, K.M., Chapman, R.W., Hirschfield, G.M., Lohse, A.W., Manns, M.P., Schrumpf, E., et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 54 (2011), 374–385.
157. Trivedi, P.J., Hirschfield, G.M., Review article: overlap syndromes and autoimmune liver disease. Aliment Pharmacol Ther 36 (2012), 517–533.
158. Czaja, A.J., Cholestatic phenotypes of autoimmune hepatitis. Clin Gastroenterol Hepatol 12 (2014), 1430–1438.
159. Lindgren, S., Glaumann, H., Almer, S., Bergquist, A., Bjornsson, E., Broome, U., et al. Transitions between variant forms of primary biliary cirrhosis during long-term follow-up. Eur J Intern Med 20 (2009), 398–402.
160. Poupon, R., Chazouilleres, O., Corpechot, C., Chretien, Y., Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 44 (2006), 85–90.
161. Efe, C., Ozaslan, E., Heurgue-Berlot, A., Kav, T., Masi, C., Purnak, T., et al. Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. Eur J Gastroenterol Hepatol 26 (2014), 532–537.
162. Chazouilleres, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., Poupon, R., Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 28 (1998), 296–301.
163. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol 63 (2015), 971–1004.
164. Manns, M.P., Czaja, A.J., Gorham, J.D., Krawitt, E.L., Mieli-Vergani, G., Vergani, D., et al. Diagnosis and management of autoimmune hepatitis. Hepatology 51 (2010), 2193–2213.
165. Alvarez, F., Berg, P.A., Bianchi, F.B., Bianchi, L., Burroughs, A.K., Cancado, E.L., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (1999), 929–938.
166. Hennes, E.M., Zeniya, M., Czaja, A.J., Pares, A., Dalekos, G.N., Krawitt, E.L., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48 (2008), 169–176.
167. Eyraud, V., Chazouilleres, O., Ballot, E., Corpechot, C., Poupon, R., Johanet, C., Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int 29 (2009), 857–864.
168. Kanzler, S., Bozkurt, S., Herkel, J., Galle, P.R., Dienes, H.P., Lohse, A.W., Presence of SLA/LP autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmune hepatitis (overlap syndrome). Dtsch Med Wochenschr 126 (2001), 450–456.
169. Muratori, P., Granito, A., Pappas, G., Pendino, G.M., Quarneti, C., Cicola, R., et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 104 (2009), 1420–1425.
170. Czaja, A.J., Carpenter, H.A., Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 34 (2001), 659–665.
171. O'Brien, C., Joshi, S., Feld, J.J., Guindi, M., Dienes, H.P., Heathcote, E.J., Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 48 (2008), 550–556.
172. Dinani, A.M., Fischer, S.E., Mosko, J., Guindi, M., Hirschfield, G.M., Patients with autoimmune hepatitis who have antimitochondrial antibodies need long-term follow-up to detect late development of primary biliary cirrhosis. Clin Gastroenterol Hepatol 10 (2012), 682–684.
173. Neuhauser, M., Bjornsson, E., Treeprasertsuk, S., Enders, F., Silveira, M., Talwalkar, J., et al. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol 105 (2010), 345–353.
174. Yang, F., Wang, Q., Wang, Z., Miao, Q., Xiao, X., Tang, R., et al. The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis. Clin Rev Allergy Immunol 50 (2016), 114–123.
175. Ozaslan, E., Efe, C., Heurgue-Berlot, A., Kav, T., Masi, C., Purnak, T., et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol 12 (2014), 863–869.
176. Chazouilleres, O., Wendum, D., Serfaty, L., Rosmorduc, O., Poupon, R., Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 44 (2006), 400–406.
177. Czaja, A.J., Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 28 (1998), 360–365.
178. Al-Chalabi, T., Portmann, B.C., Bernal, W., McFarlane, I.G., Heneghan, M.A., Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 28 (2008), 209–220.
179. Wang, Q., Selmi, C., Zhou, X., Qiu, D., Li, Z., Miao, Q., et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun 41 (2013), 140–145.
180. Lohse, A.W., zum Buschenfelde, K.H., Franz, B., Kanzler, S., Gerken, G., Dienes, H.P., Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 29 (1999), 1078–1084.
181. Jacoby, A., Rannard, A., Buck, D., Bhala, N., Newton, J.L., James, O.F.W., et al. Development, validation and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut 54 (2005), 1622–1629.
182. Newton, J.L., Bhala, N., Burt, J., Jones, D.E.J., Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. J Hepatol 44 (2006), 776–782.
183. Beuers, U., Kremer, A.E., Bolier, R., Elferink, R.P., Pruritus in cholestasis: facts and fiction. Hepatology 60 (2014), 399–407.
184. Sherlock, S., Scheuer, P.J., The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 289 (1973), 674–678.
185. Summerfield, J.A., Elias, E., Hungerford, G.D., Nikapota, V.L., Dick, R., Sherlock, S., The biliary system in primary biliary cirrhosis. A study by endoscopic retrograde cholangiopancreatography. Gastroenterology 70 (1976), 240–243.
186. Datta, D.V., Sherlock, S., Cholestyramine for long term relief of the priritus complicating intrahepatic cholestasis. Gastroenterology 50 (1966), 323–332.
187. Rust, C., Sauter, G.H., Oswald, M., Buttner, J., Kullak-Ublick, G.A., Paumgartner, G., et al. Effect of cholestyramine on bile acid patterns and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest 30 (2000), 135–139.
188. Kuiper, E.M., van Erpecum, K.J., Beuers, U., Hansen, B.E., Thio, H.B., de Man, R.A., et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 52 (2010), 1334–1340.
189. Kremer, A.E., van Dijk, R., Leckie, P., Schaap, F.G., Kuiper, E.M.M., Mettang, T., et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions. Hepatology 56 (2012), 1391–1400.
190. Ghent, C.N., Carruthers, S.G., Treatment of pruritus in primary biliary cirrhosis with rifampicin. Results of a double-blind, crossover, randomized trial. Gastroenterology 94 (1988), 488–493.
191. Bachs, L.P., Pares, A., Elena, M., Piera, C., Rodes, J., Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1 (1989), 574–576.
192. Podesta, A.L., Terg, P., Villamil, R., Flores, F., Mastai, D., Udaondo, R., et al. Treatment of pruritus in primary biliary cirrhosis with rifampicin. Results of a double-blind, cross-over, randomized trial. Gastroenterology 94 (1991), 488–493.
193. Bachs, L.P., Elena, M., Piera, M., Rodes, J., Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102 (1992), 2077–2080.
194. Tandon, P., Rowe, B.H., Vandermeer, B., Bain, V.G., The efficacy and safety of bile acid binding agents, opioid antagonists or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 102 (2007), 1528–1536.
195. Khurana, S., Singh, P., Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 26 (2006), 943–948.
196. Prince, M.I., Burt, A.D., Jones, D.E.J., Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 50 (2002), 436–439.
197. Sampaziotis, F., Griffiths, W.J., Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus. Br J Clin Pharmacol 73 (2012), 826–827.
198. Bergasa, N.V., Talbot, T.L., Alling, D.W., Schmitt, J.M., Walker, E.C., Baker, B.L., et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 102 (1992), 544–549.
199. Wolfhagen, F.H.J., Sternieri, E., Hop, W.C.J., Vitale, G., Bertoletti, M., Van Buuren, H.R., Oral naltrexone for cholestatic pruritus-a double-blind, placebo-controlled study. Gastroenterology 113 (1997), 1264–1269.
200. Terg, R., Coronel, E., Sorda, J., Munoz, A.E., Findor, J., Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 37 (2002), 717–722.
201. Jones, E.A., Neuberger, J.M., Bergasa, N.V., Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. Q J Med 95 (2002), 547–552.
202. McRae, C.A., Prince, M.I., Hudson, M., Day, C.P., James, O.F.W., Jones, D.E.J., Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 125 (2003), 591–596.
203. Jones, E.A., Dekker, R.L., Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 118 (2000), 431–432.
204. Mayo, M.J., Handem, I., Saldana, S., Jacobe, H., Getachew, Y., Rush, A.J., Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 45 (2007), 666–674.
205. Bergasa, N.V., McGee, M., Ginsburg, I.H., Engler, D., Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology 44 (2006), 1317–1323.
206. Beuers, U., Gerken, G., Pusl, T., Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology 44 (2006), 280–281.
207. Hofmann, A.F., Huet, P.M., Nasobiliary drainage for cholestatic pruritus. Hepatology 43 (2006), 1170–1171.
208. Hegade, V.S., Krawczyk, M., Kremer, A.E., Kuczka, J., Gaouar, F., Kuiper, E.M., et al. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment Pharmacol Ther 43 (2016), 294–302.
209. Pares, A., Herrera, M., Aviles, J., Sanz, M., Mas, A., Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 53 (2010), 307–312.
210. Decock, S., Roelandts, R., Steenbergen, W.V., Laleman, W., Cassiman, D., Verslype, C., et al. Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. J Hepatol 57 (2012), 637–641.
211. Leckie, P., Tritto, G., Mookerjee, R., Davies, N., Jones, D.E.J., Jalan, R., “Out-patient” albumin dialysis for cholestatic patients with intractable itch. Aliment Pharmacol Therap 35 (2012), 696–704.
212. Gross, C.R., Malinchoc, M., Kim, W.R., Evans, R.W., Wiesner, R.H., Petz, J.L., et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 29 (1999), 356–364.
213. Kremer, A.E., martens, J.J., Kulik, W., Rueff, F., Kuiper, E.M., van Buuren, H.R., et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 139 (2010), 1008–1018.
214. Hegade, V.S., Kendrick, S.F., Dobbins, R.L., Miller, S.R., Thompson, D., Richards, D., et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet 389 (2017), 1114–1123.
215. Huet, P.-M., Deslauriers, J., Faucher, C., Charbonneau, J., Fatigue, mental health and depression in patients with primary biliary cirrhosis (PBC). Hepatology, 24, 1996, 167A.
216. Cauch-Dudek, K., Abbey, S., Stewart, D.E., Heathcote, E.J., Fatigue in primary biliary cirrhosis. Gut 43 (1998), 705–710.
217. Huet, P.M., Deslauriers, J., Tran, A., Faucher, C., Charbonneau, J., Impact of fatigue on the quality of life in patients with primary biliary cirrhosis. Am J Gastroenterol 95 (2000), 760–767.
218. Goldblatt, J., Taylor, P.J.S., Lipman, T., Prince, M., Baragiotta, M., Bassendine, M.F., et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 122 (2002), 1235–1241.
219. Newton, J.L., Hollingsworth, K.G., Taylor, R., El-Sharkawy, A.M., Khan, Z.U., Pearce, R., et al. Cognitive impairment in primary biliary cirrhosis: symtpom impact and potential aetiology. Hepatology 48 (2008), 541–549.
220. Hollingsworth, K.G., Newton, J.L., Taylor, R., McDonald, C., Palmer, J.M., Blamire, A.M., et al. A pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis. Clin Gastroenterol Hepatol 6 (2008), 1041–1048.
221. Carbone, M., Bufton, S., Monaco, A., Griffiths, L., Jones, D.E., Neuberger, J.M., The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol 59 (2013), 490–494.
222. Jones, D.E., Sutcliffe, K., Pairman, J., Wilton, K., Newton, J.L., An integrated care pathway improves quality of life in Primary Biliary Cirrhosis. QJM 101 (2008), 535–543.
223. Watt, F.E., James, O.F.W., Jones, D.E.J., Patterns of autoimmunity in PBC patients and their families. QJM 97 (2004), 397–406.
224. Hollingsworth, K.G., Newton, J.L., Robinson, L., Taylor, R., Blamire, A.M., Jones, D.E.J., Loss of capacity to recover from acidosis in repeat exercise is strongly associated with fatigue in primary biliary cirrhosis. J Hepatol 53 (2010), 155–161.
225. Mang, F.W., Michieletti, P., O'Rourke, K., Cauch-Dudek, K., Diamant, N., Bookman, A., et al. Primary biliary cirrhosis, sicca complex, and dysphagia. Dysphagia 12 (1997), 167–170.
226. Tsifetaki, N., Kitsos, G., Paschides, C.A., Alamanos, Y., Eftaxias, V., Voulgari, P.V., et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren's syndrome: a randomised 12 week controlled study. Ann Rheum Dis 62 (2003), 1204–1207.
227. Ono, M., Takamura, E., Shinozaki, K., Tsumura, T., Hamano, T., Yagi, Y., et al. Therapeutic effect of cevimeline on dry eye in patients with Sjogren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol 138 (2004), 6–17.
228. Kruszka, P., O'Brian, R.J., Diagnosis and management of Sjogren syndrome. Am Fam Physician 79 (2009), 465–470.
229. Excellence NIfHaC. Raynaud's Phenomenon NICE Clinical Knowledge Summary. 2014 [cited; Available from: http://cks.nice.org.uk/raynauds-phenomenon – !scenario.
230. Guanabens, N., Pares, A., Ros, I., Caballeria, L., Pons, F., Vidal, S., et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 42 (2005), 573–577.
231. Pares, A., Guanabens, N., Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis 12 (2008), 407–424 x.
232. Guanabens, N., Cerda, D., Monegal, A., Pons, F., Caballeria, L., Peris, P., et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 138 (2010), 2348–2356.
233. Guanabens, N., Monegal, A., Cerda, D., Muxi, A., Gifre, L., Peris, P., et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology 58 (2013), 2070–2078.
234. Cryer, B., Bauer, D.C., Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?. Mayo Clin Proc 77 (2002), 1031–1043.
235. Treeprasertsuk, S., Silveira, M.G., Petz, J.L., Lindor, K.D., Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. Am J Ther 18 (2011), 375–381.
236. Pereira, S.P., O'Donohue, J., Moniz, C., Phillips, M.G., Abraha, H., Buxton-Thomas, M., et al. Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial. Aliment Pharmacol Ther 19 (2004), 563–570.
237. Newton, J., Francis, R., Prince, M., James, O., Bassendine, M., Rawlings, D., et al. Osteoporosis in primary biliary cirrhosis revisited. Gut 49 (2001), 282–287.
238. Kaplan, M.M., Elta, G.H., Furie, B., Sadowski, J.A., Russell, R.M., Fat-soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology 95 (1988), 787–792.
239. Phillips, J.R., Angulo, P., Petterson, T., Lindor, K.D., Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 96 (2001), 2745–2750.
240. Maillette de Buy Wenniger, L., Beuers, U., Bile salts and cholestasis. Dig Liver Dis 42 (2010), 409–418.
241. Jahn, C.E., Schaefer, E.J., Taam, L.A., Hoofnagle, J.H., Lindgren, F.T., Albers, J.J., et al. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 89 (1985), 1266–1278.
242. Kew, M.C., Varma, R.R., Dos Santos, H.A., Scheuer, P.J., Sherlock, S., Portal hypertension in primary biliary cirrhosis. Gut 12 (1971), 830–834.
243. Gores, G.J., Wiesner, R.H., Dickson, E.R., Zinsmeister, A.R., Jorgensen, R.A., Langworthy, A., Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology 96 (1989), 1552–1559.
244. Abraham, S.C., Kamath, P.S., Eghtesad, B., Demetris, A.J., Krasinskas, A.M., Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am J Surg Pathol 30 (2006), 1454–1461.
245. Ali, A.H., Sinakos, E., Silveira, M.G., Jorgensen, R.A., Angulo, P., Lindor, K.D., Varices in early histological stage primary biliary cirrhosis. J Clin Gastroenterol 45 (2011), e66–e71.
246. Levy, C., Zein, C.O., Gomez, J., Soldevila-Pico, C., Firpi, R., Morelli, G., et al. Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 5 (2007), 803–808.
247. Bressler, B., Pinto, R., El-Ashry, D., Heathcote, E.J., Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection?. Gut 54 (2005), 407–410.
248. de Franchis, R., Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 63 (2015), 743–752.
249. Jones, D.E., Metcalf, J.V., Collier, J.D., Bassendine, M.F., James, O.F., Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 26 (1997), 1138–1142.
250. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
251. Adam, R., Karam, V., Delvart, V., O'Grady, J., Mirza, D., Klempnauer, J., et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 57 (2012), 675–688.
252. Singal, A.K., Guturu, P., Hmoud, B., Kuo, Y.F., Salameh, H., Wiesner, R.H., Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 95 (2013), 755–760.
253. Carbone, M., Neuberger, J.M., Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol 60 (2014), 210–223.
254. Martin, P., DiMartini, A., Feng, S., Brown, R. Jr., Fallon, M., Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 59 (2014), 1144–1165.
255. European Association for the Study of the Liver. Electronic address eee. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 64 (2016), 433–485.
256. Pells, G., Mells, G.F., Carbone, M., Newton, J.L., Bathgate, A.J., Burroughs, A.K., et al. The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort. J Hepatol 59 (2013), 67–73.
257. Lucey, M.R., Terrault, N., Ojo, L., Hay, J.E., Neuberger, J., Blumberg, E., et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 19 (2013), 3–26.
258. Silveira, M.G., Talwalkar, J.A., Lindor, K.D., Wiesner, R.H., Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant 10 (2010), 720–726.
259. Bosch, A., Dumortier, J., Maucort-Boulch, D., Scoazec, J.Y., Wendum, D., Conti, F., et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. J Hepatol 63 (2015), 1449–1458.
260. Pearce, R.M., Jones, D.E., Newton, J.L., Development of an evidence-based patient information medium: empowering newly diagnosed patients with primary biliary cirrhosis. J Vis Commun Med 34 (2011), 4–13.
261. Blackburn, P., Freeston, M., Baker, C.R., Jones, D.E., Newton, J.L., The role of psychological factors in the fatigue of primary biliary cirrhosis. Liver Int 27 (2007), 654–661.